[HTML][HTML] SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …
and are especially important in high-risk individuals where vaccination is not an option …
Animal models for COVID-19: advances, gaps and perspectives
C Fan, Y Wu, X Rui, Y Yang, C Ling, S Liu… - Signal transduction and …, 2022 - nature.com
Abstract COVID-19, caused by SARS-CoV-2, is the most consequential pandemic of this
century. Since the outbreak in late 2019, animal models have been playing crucial roles in …
century. Since the outbreak in late 2019, animal models have been playing crucial roles in …
Viral dynamics and duration of PCR positivity of the SARS-CoV-2 Omicron variant
Abstract Background The Omicron SARS-CoV-2 variant is responsible for a major wave of
COVID-19, with record case counts reflecting high transmissibility and escape from prior …
COVID-19, with record case counts reflecting high transmissibility and escape from prior …
Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history
W Wang, S Lusvarghi, R Subramanian, NJ Epsi… - Cell host & …, 2022 - cell.com
The rapid emergence of SARS-CoV-2 variants challenges vaccination strategies. Here, we
collected 201 serum samples from persons with a single infection or multiple vaccine …
collected 201 serum samples from persons with a single infection or multiple vaccine …
Susceptibility of SARS-CoV-2 Omicron variants to therapeutic monoclonal antibodies: systematic review and meta-analysis
ABSTRACT SARS-CoV-2 Omicron variants contain many mutations in its spike receptor-
binding domain, the target of all authorized monoclonal antibodies (MAbs). Determining the …
binding domain, the target of all authorized monoclonal antibodies (MAbs). Determining the …
Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort study
Background: The combined impact of immunity and SARS-CoV-2 variants on viral kinetics
during infections has been unclear. Methods: We characterized 1,280 infections from the …
during infections has been unclear. Methods: We characterized 1,280 infections from the …
Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients
Y Nguyen, A Flahault, N Chavarot, C Melenotte… - Clinical Microbiology …, 2022 - Elsevier
Objective Immunocompromised patients have an increased risk of a severe form of COVID-
19. The clinical efficacy of the tixagevimab/cilgavimab monoclonal antibody combination as …
19. The clinical efficacy of the tixagevimab/cilgavimab monoclonal antibody combination as …
[HTML][HTML] Antigenic evolution of SARS coronavirus 2
AZ Mykytyn, RAM Fouchier, BL Haagmans - Current Opinion in Virology, 2023 - Elsevier
SARS coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, emerged in China in
December 2019. Vaccines developed were very effective initially, however, the virus has …
December 2019. Vaccines developed were very effective initially, however, the virus has …
Recent insights into SARS‐CoV‐2 omicron variant
The SARS‐CoV‐2 omicron variant (B. 1.1. 529) was first identified in Botswana and South
Africa, and its emergence has been associated with a steep increase in the number of SARS …
Africa, and its emergence has been associated with a steep increase in the number of SARS …
Monoclonal antibody levels and protection from COVID-19
Multiple monoclonal antibodies have been shown to be effective for both prophylaxis and
therapy for SARS-CoV-2 infection. Here we aggregate data from randomized controlled …
therapy for SARS-CoV-2 infection. Here we aggregate data from randomized controlled …